Future Directions in Metastatic Castration-Resistant Prostate Cancer

Dr. Pedro Barata and Dr. Johann De Bono conclude the discussion by reflecting on the evolving future of radiopharmaceutical therapies in metastatic castration-resistant prostate cancer (mCRPC) and the broader direction of prostate cancer care. Dr. De Bono emphasizes that advances in treatment are increasingly transforming metastatic prostate cancer into a chronic disease, with many patients expected to live significantly longer while maintaining quality of life. The faculty discuss the growing importance of individualized treatment planning, including careful consideration of sequencing, duration of therapy, treatment holidays, and long-term toxicity monitoring as radiopharmaceutical options continue to expand. Dr. De Bono also highlights the anticipated role of radiopharmaceuticals within a larger therapeutic armamentarium that includes next-generation PSMA-targeted therapies, actinium-based approaches, and other emerging treatment modalities. Together, the faculty underscore the importance of continued clinical research, multidisciplinary care, and evidence-based decision-making to optimize long-term outcomes and quality of life for patients living with mCRPC.